C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 121 filers reported holding C4 THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,408,798 | -67.4% | 737,835 | -42.4% | 0.00% | -50.0% |
| Q1 2024 | $10,467,747 | +1532.1% | 1,281,242 | +1028.7% | 0.00% | – |
| Q4 2023 | $641,349 | +57.6% | 113,513 | -48.1% | 0.00% | – |
| Q3 2023 | $406,825 | -35.8% | 218,723 | -5.1% | 0.00% | – |
| Q2 2023 | $634,057 | -41.6% | 230,566 | -33.3% | 0.00% | – |
| Q1 2023 | $1,085,131 | -35.2% | 345,583 | +21.7% | 0.00% | – |
| Q4 2022 | $1,675,317 | +45289.2% | 283,952 | -32.5% | 0.00% | -100.0% |
| Q3 2022 | $3,691 | +271.7% | 420,843 | +219.5% | 0.00% | – |
| Q2 2022 | $993 | -100.0% | 131,724 | +10.0% | 0.00% | -100.0% |
| Q1 2022 | $2,906,000 | -59.9% | 119,789 | -46.7% | 0.00% | 0.0% |
| Q4 2021 | $7,241,000 | -38.6% | 224,848 | -14.8% | 0.00% | -66.7% |
| Q3 2021 | $11,794,000 | +35.0% | 263,964 | +14.3% | 0.00% | +50.0% |
| Q2 2021 | $8,739,000 | +1990.7% | 230,963 | +1729.6% | 0.00% | – |
| Q4 2020 | $418,000 | – | 12,624 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 6,880,527 | $31,788,035 | 11.47% |
| Soleus Capital Management, L.P. | 4,051,996 | $18,720,222 | 1.65% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,442,841 | $6,665,925 | 1.57% |
| COMMODORE CAPITAL LP | 3,410,384 | $15,755,974 | 1.08% |
| TCG Crossover Management, LLC | 1,276,574 | $5,897,772 | 0.62% |
| Bain Capital Life Sciences Investors, LLC | 1,111,910 | $5,137,024 | 0.56% |
| RA Capital Management | 4,878,000 | $22,536,360 | 0.30% |
| Atom Investors LP | 332,620 | $1,536,704 | 0.15% |
| Orbimed Advisors | 1,513,058 | $6,990,328 | 0.14% |
| WASATCH ADVISORS LP | 4,847,150 | $22,393,833 | 0.12% |